Response to Letter Regarding Article, "Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial".

Autor: Shahbaznejad L; Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Davoudi A; Antimicrobial Resistance Research Center, Department of Infectious Diseases, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Eslami G; Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran., Markowitz JS; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida., Navaeifar MR; Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Hosseinzadeh F; Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Movahedi FS; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran., Rezai MS; Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: drmsrezaii@yahoo.com.
Jazyk: angličtina
Zdroj: Clinical therapeutics [Clin Ther] 2021 Sep; Vol. 43 (9), pp. 1624-1626. Date of Electronic Publication: 2021 Aug 05.
DOI: 10.1016/j.clinthera.2021.07.006
Databáze: MEDLINE